Eisai opens doors at $200M cancer drug R&D shop

After committing $200 million to the personalized cancer R&D unit, Japanese drugmaker Eisai officially opened the doors of the group, called H3 Biomedicine, in Cambridge, MA, this week. H3 Biomedicine, which aims to discover cancer drugs that attack the specific drivers of patients' tumors, plans to build up its staff to 70 people over the next year and expand beyond its 24,000 square feet of lab space. The group now employs 30 workers. Article | Release

Read more on